FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024894637> ?p ?o ?g. }

• W2024894637 endingPage "889" @default.
• W2024894637 startingPage "883" @default.
• W2024894637 abstract "Septic arthritis is associated with residual dysfunction in 10 to 25% of affected children. Concentrations of cytokines detected in synovial fluid of children with bacterial arthritis correlate with the severity of inflammation. Treatment with dexamethasone decreased cartilage degradation in experimental Haemophilus influenzae b and Staphylococcus aureus arthritis.To decrease the number of patients with residual dysfunction of the affected joint at the end of therapy and at 6 and 12 months and to speed clinical recovery by the administration of dexamethasone.In a double blind manner we randomly selected 123 children with suspected hematogenous bacterial arthritis to receive dexamethasone or saline for 4 days. Antibiotic therapy was tailored according to age and the recovered pathogen.Of the 123 children enrolled, 61 were assigned to the dexamethasone group and 62 to the placebo group. Only 50 and 50 patients in each group were evaluable. The 2 groups of patients were comparable with respect to age, sex, duration of symptoms, pathogen, affected joint and therapeutic and diagnostic procedures. Staphylococcus aureus accounted for 67% of the isolates, Haemophilus influenzae type b for 13% and Streptococcus pneumoniae for 9%. Dexamethasone therapy reduced residual dysfunction at the end of therapy, P = 0.000068; at 6 months, P = 0.00007; and at 12 months, P = 0.00053 of follow-up and shortened the duration of symptoms (P = 0.001) during the acute phase. The 26% incidence of residual dysfunction in the control patients was similar to the 25% found in other series.A short course of dexamethasone reduced residual joint dysfunction and shortened significantly the duration of symptoms in children with documented hematogenous septic arthritis. These results suggest that a 4-day course of low dose dexamethasone given early benefits children with hematogenous septic arthritis." @default.
• W2024894637 created "2016-06-24" @default.
• W2024894637 creator A5002686868 @default.
• W2024894637 creator A5009270651 @default.
• W2024894637 creator A5019652670 @default.
• W2024894637 creator A5023001720 @default.
• W2024894637 creator A5024286629 @default.
• W2024894637 creator A5024877634 @default.
• W2024894637 creator A5035120846 @default.
• W2024894637 creator A5081346453 @default.
• W2024894637 creator A5089460799 @default.
• W2024894637 date "2003-10-01" @default.
• W2024894637 modified "2023-10-16" @default.
• W2024894637 title "Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children" @default.
• W2024894637 cites W1895946897 @default.
• W2024894637 cites W1971522164 @default.
• W2024894637 cites W1994263351 @default.
• W2024894637 cites W1997511059 @default.
• W2024894637 cites W2002475242 @default.
• W2024894637 cites W2004476708 @default.
• W2024894637 cites W2006364047 @default.
• W2024894637 cites W2073619436 @default.
• W2024894637 cites W2092805910 @default.
• W2024894637 cites W2136327887 @default.
• W2024894637 cites W2143575530 @default.
• W2024894637 doi "https://doi.org/10.1097/01.inf.0000091293.32187.7b" @default.
• W2024894637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14551489" @default.
• W2024894637 hasPublicationYear "2003" @default.
• W2024894637 type Work @default.
• W2024894637 sameAs 2024894637 @default.
• W2024894637 citedByCount "124" @default.
• W2024894637 countsByYear W20248946372012 @default.
• W2024894637 countsByYear W20248946372013 @default.
• W2024894637 countsByYear W20248946372014 @default.
• W2024894637 countsByYear W20248946372015 @default.
• W2024894637 countsByYear W20248946372016 @default.
• W2024894637 countsByYear W20248946372017 @default.
• W2024894637 countsByYear W20248946372018 @default.
• W2024894637 countsByYear W20248946372019 @default.
• W2024894637 countsByYear W20248946372020 @default.
• W2024894637 countsByYear W20248946372021 @default.
• W2024894637 countsByYear W20248946372022 @default.
• W2024894637 countsByYear W20248946372023 @default.
• W2024894637 crossrefType "journal-article" @default.
• W2024894637 hasAuthorship W2024894637A5002686868 @default.
• W2024894637 hasAuthorship W2024894637A5009270651 @default.
• W2024894637 hasAuthorship W2024894637A5019652670 @default.
• W2024894637 hasAuthorship W2024894637A5023001720 @default.
• W2024894637 hasAuthorship W2024894637A5024286629 @default.
• W2024894637 hasAuthorship W2024894637A5024877634 @default.
• W2024894637 hasAuthorship W2024894637A5035120846 @default.
• W2024894637 hasAuthorship W2024894637A5081346453 @default.
• W2024894637 hasAuthorship W2024894637A5089460799 @default.
• W2024894637 hasConcept C126322002 @default.
• W2024894637 hasConcept C141071460 @default.
• W2024894637 hasConcept C142724271 @default.
• W2024894637 hasConcept C204787440 @default.
• W2024894637 hasConcept C27081682 @default.
• W2024894637 hasConcept C2775956843 @default.
• W2024894637 hasConcept C2776925733 @default.
• W2024894637 hasConcept C2777077863 @default.
• W2024894637 hasConcept C2779489039 @default.
• W2024894637 hasConcept C2780401358 @default.
• W2024894637 hasConcept C2781253189 @default.
• W2024894637 hasConcept C501593827 @default.
• W2024894637 hasConcept C523546767 @default.
• W2024894637 hasConcept C54355233 @default.
• W2024894637 hasConcept C71924100 @default.
• W2024894637 hasConcept C86803240 @default.
• W2024894637 hasConcept C89423630 @default.
• W2024894637 hasConcept C90924648 @default.
• W2024894637 hasConceptScore W2024894637C126322002 @default.
• W2024894637 hasConceptScore W2024894637C141071460 @default.
• W2024894637 hasConceptScore W2024894637C142724271 @default.
• W2024894637 hasConceptScore W2024894637C204787440 @default.
• W2024894637 hasConceptScore W2024894637C27081682 @default.
• W2024894637 hasConceptScore W2024894637C2775956843 @default.
• W2024894637 hasConceptScore W2024894637C2776925733 @default.
• W2024894637 hasConceptScore W2024894637C2777077863 @default.
• W2024894637 hasConceptScore W2024894637C2779489039 @default.
• W2024894637 hasConceptScore W2024894637C2780401358 @default.
• W2024894637 hasConceptScore W2024894637C2781253189 @default.
• W2024894637 hasConceptScore W2024894637C501593827 @default.
• W2024894637 hasConceptScore W2024894637C523546767 @default.
• W2024894637 hasConceptScore W2024894637C54355233 @default.
• W2024894637 hasConceptScore W2024894637C71924100 @default.
• W2024894637 hasConceptScore W2024894637C86803240 @default.
• W2024894637 hasConceptScore W2024894637C89423630 @default.
• W2024894637 hasConceptScore W2024894637C90924648 @default.
• W2024894637 hasIssue "10" @default.
• W2024894637 hasLocation W20248946371 @default.
• W2024894637 hasLocation W20248946372 @default.
• W2024894637 hasOpenAccess W2024894637 @default.
• W2024894637 hasPrimaryLocation W20248946371 @default.
• W2024894637 hasRelatedWork W144432457 @default.
• W2024894637 hasRelatedWork W1997440245 @default.
• W2024894637 hasRelatedWork W2026514246 @default.
• W2024894637 hasRelatedWork W2096228389 @default.

• next